{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:24:33Z","timestamp":1791415473294,"version":"4.3.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ebiom.2025.105819","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:03:26Z","timestamp":1751357006000},"page":"105819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Integrated virologic analysis of resistance to nirmatrelvir\/ritonavir in individuals across four phase 2\/3 clinical studies for the treatment of COVID-19"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-7231","authenticated-orcid":false,"given":"Mary Lynn","family":"Baniecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunjie","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra K.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda D.","family":"Cardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2025.105819_bib1","series-title":"Full prescribing information","year":"2023"},{"key":"10.1016\/j.ebiom.2025.105819_bib2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2025.105819_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/10915818221095489","article-title":"Comprehensive nonclinical safety assessment of nirmatrelvir supporting timely development of the SARS-COV-2 antiviral therapeutic, Paxlovid\u2122","volume":"41","author":"Sathish","year":"2022","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.ebiom.2025.105819_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2025.105819_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00221-X","article-title":"Extended nirmatrelvir\/ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a randomized, double-blind, phase 2 trial","author":"Weinstein","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105819_bib6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2025.105819_bib7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with COVID-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2025.105819_bib8","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","article-title":"SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis","volume":"5","author":"Raglow","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ebiom.2025.105819_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35431","article-title":"Emerging SARS-CoV-2 resistance after antiviral treatment","volume":"7","author":"Tamura","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ebiom.2025.105819_bib10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.chembiol.2024.03.008","article-title":"SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs","volume":"31","author":"Iketani","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ebiom.2025.105819_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2018.07.020","article-title":"Comparison of antiviral resistance across acute and chronic viral infections","volume":"158","author":"Mason","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ebiom.2025.105819_bib12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","article-title":"De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report","volume":"13","author":"Gandhi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2025.105819_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ebiom.2025.105819_bib15","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1038\/s41467-022-32665-7","article-title":"Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2025.105819_bib16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2025.105819_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl4013","article-title":"In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance","volume":"10","author":"Zhu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.ebiom.2025.105819_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.ebiom.2025.105819_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02815-22","article-title":"The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir","volume":"14","author":"Jochmans","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.ebiom.2025.105819_bib20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID's role in pandemic response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.ebiom.2025.105819_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jmoldx.2022.05.007","article-title":"Clinical performance characteristics of the swift normalase amplicon panel for sensitive recovery of severe acute respiratory syndrome coronavirus 2 genomes","volume":"24","author":"Shrestha","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ebiom.2025.105819_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2144\/000112096","article-title":"Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli","volume":"40","author":"Tischer","year":"2006","journal-title":"Biotechniques"},{"key":"10.1016\/j.ebiom.2025.105819_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101972","article-title":"Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants","volume":"298","author":"Greasley","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ebiom.2025.105819_bib27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","article-title":"Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir","volume":"622","author":"Duan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2025.105819_bib28","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1038\/s41467-024-51924-3","article-title":"Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections","volume":"15","author":"Nooruzzaman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2025.105819_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/cid\/ciad494","article-title":"Nirmatrelvir resistance\u2014de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure\u2014a case report","volume":"78","author":"Zuckerman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105819_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.medj.2023.08.001","article-title":"Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2","volume":"4","author":"Hirotsu","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.ebiom.2025.105819_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29337","article-title":"No emergence of resistance mutations in COVID-19 patients receiving nirmatrelvir\/ritonavir","volume":"96","author":"Palomino-Cabrera","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.ebiom.2025.105819_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/v16050718","article-title":"Nirmatrelvir resistance in an immunocompromised patient with persistent coronavirus disease 2019","volume":"16","author":"Yamamoto","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ebiom.2025.105819_bib33","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1093\/cid\/ciac512","article-title":"Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19)","volume":"76","author":"Boucau","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105819_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/cid\/ciac663","article-title":"Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir\/ritonavir treatment","volume":"76","author":"Epling","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425002634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425002634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:02:27Z","timestamp":1755496947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425002634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"alternative-id":["S2352396425002634"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105819","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated virologic analysis of resistance to nirmatrelvir\/ritonavir in individuals across four phase 2\/3 clinical studies for the treatment of COVID-19","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105819"}}